Sydney M Crago

Naor is stepping down to pursue new opportunities and will be replaced by Kenneth Sall, MD who has been appointed as Opthea’s Senior Medical Advisor.

This allosteric tyrosine kinase (TYK2) inhibitor may help to treat the disregulation of TYK2 mediated pathways may also play an important role in conditions, including noninfectious uveitis.

This trial is testing tinlarebant, a novel oral therapy which is intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to geographic atrophy (GA).

The PHOTON study demonstrates the long-term efficacy and safety of this treatment for patients with DME.

This investigational new drug application was cleared for the company’s phase I/II clinical trial.

The fellowship is a one-year program that will provide comprehensive training to residency graduates in the latest advancements in ophthalmology, including diagnostic and therapeutic techniques, surgical procedures, and clinical research.

Intergalactic's non-viral gene therapy platform is designed to overcome limitations of standard adeno-associated virus (AAV) gene therapy technologies.

The two-hour event will share details on the company’s clinical programs for retina diseases through formal presentations and a live Q&A session.

The study demonstrated a meaningful increase in the long chain and very long chain polyunsaturated fatty acids whose deficit is associated with dry AMD.

Get caught up on the approvals and hear directly from Kaushal Solanki, PhD, Founder and CEO of Eyenuk.

The company announced the Complete Letter Response from the FDA for the Biologics License Application for aflibercept 8 mg is “solely due to an ongoing review of inspection findings at a third-party filler.”

The study will include 100 patients with the aim of determining effective and ineffective standards of eye injections for AMD to better personalize future medical evaluations.

The certification will allow 20/20 Onsite to make clinical trials more accessible to patients nationwide and expand site options for sponsors while maintaining performance and data collection standards, including BCVA and DR testing.

This phase will evaluate UNITY’s UBX1325 (foselutoclax) in a head-to-head comparison with aflibercept for the treatment of diabetic macular edema (DME).

Modern Retina is looking back at the first half of 2023 as we explore the role of AI in the retinal field in anticipation of the changes to come.

EyeBio has begun the dosing of the first participants in its Phase 1b/2 AMARONE clinical trial for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD).

The open source article reports on the anti-inflammatory compound and its potential to treat retinal diseases.

This approval will allow Belite Bio to initiate the phase 3 clinical trial in South Korea, also known as the DRAGON study.

This two-in-one option, PreserVision AREDS 2 Formula eye vitamins plus CoQ10 combines the exact nutrient formula recommended by the National Eye Institute (NEI) to help reduce the risk of moderate to advanced Age-related Macular Degeneration (AMD) progression.

The 12-month data demonstrated maintenance of controlled wet AMD subjects comparable to aflibercept injections every eight weeks with a single administration of OTX-TKI.

The company’s pipeline includes treatments for XLRP, AMD, and cone-rod dystrophy (CRD).

OTX-TKI is the Ocular Therapeutix’s axitinib intravitreal implant that is being developed for the treatment of diabetic retinopathy, wet AMD and other retinal diseases.

Ocular Therapeutix is scheduled to present trial results as well as participate in a panel discussion and sponsor a presentation at the 2023 Clinical Trials at the Summit Annual Meeting.

PAVIA is a 12-month, randomized, controlled phase 2 clinical trial of EYP-1901 in patients with moderate to severe NPDR.

This funding will allow for the registration and launch of gilderuretinol, the first and only medicine in clinical development to address the underlying mechanism of Stargardt disease.

Intelligent Retinal Imaging Systems (IRIS) celebrates the company’s 1 millionth diabetic retinal exam.

Aviceda Therapeutics doses its first patient with AVD-104 in its Phase 2 SIGLEC Trial. This intravitreal asset is being tried for treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

VABYSMO is the first treatment for wet AMD and DME in Canada that acts by targeting both VEGF-A and Ang-2, two key drivers of vascular instability that have been associated with vision-threatening retinal conditions.

The company is currently developing treatments for age related macular degeneration as injections and eye drops, among others.

Data supports ANX007 as the first complement therapy to preserve visual acuity, achieving statistically significant protection, but reduction in rate of geographic atrophy lesion growth did not reach statistical significance.